BioSpace News Archive

Nov. 5, 2020 12:15 UTC Acceleron Announces Third Quarter 2020 REBLOZYL ® Net Sales - Acceleron expects to report approximately $19.3 million in royalty revenue for Q3 2020 from approximately $96 million in net sales of REBLOZYL ® (luspatercept-aamt) as reported by Bristol Myers Squibb - - Acceleron will report its full third quarter 2020 financial and operating results after the close of U.S. financial markets today, November 5, 2020,

Company recently earned a $ 25 million milestone payment as NIS793 advanced to Phase 2 development in advanced pancreatic cancer An u ndisclosed partner entered Phase 2 development, triggering a $0.5 million milestone Rezolute’s financing resulted in accelerated $1.4 million payment Two partners presented early stage data at scientific conferences Acquired royalty interest in four lysosomal storage disorder enzymes being developed by Chiesi Group

On track to dose first patient by year-end with NTLA-2001 for the treatment of transthyretin amyloidosis (ATTR) , following regulatory authorization to initiate Phase 1 clinical trial Anticipate s submit ting an IND or IND-equivalent for lead TCR-T cell therapy, NTLA-5001 for the treatment of acute myeloid leukemia (AML) , in 1H 2021 Expect s to submit an IND or IND-equivalent for NTLA-200 2 for the treatment of hereditary angioedema (HAE) in 2H 2

– Preliminary data from first-in-human trial of menin inhibitor KO-539 accepted for oral presentation at ASH – – Encouraging safety, tolerability and activity with KO-539 highlighted in ASH abstract – – Preclinical data support expansion opportunity for tipifarnib plus PI3Kα inhibitor in HRAS- and/or PI3K-dependent tumors – – $325.4 million in cash, cash equivalents and investments provide runway into 2023 – – Management to host webcast and conference call today at 8:00 a.m. ET –

Phase 3 DISSOLVE clinical program with Sobi ongoing to evaluate SEL-212; topline data expected in the second half of 2022 IND filing for gene therapy expected in Q1 2021; preliminary Phase 1 data expected by end of 2021 IgA nephropathy program underway with IND expected by end of 2021 Ended quarter with cash position of $147.6 million with runway into the first quarter of 2023 Company to host conference call today at 8:30 a.m. ET

Crescita Therapeutics Inc. today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co. Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products

Secured a development funding agreement related to elamipretide Phase 2b dry AMD study enrollment completion targeted by year-end Barth NDA preparation underway SBT-272 shows promise in additional neurological disease preclinical models Management to host conference call today at 8:30am ET

Advancement Follows ASCO 2020 Data Validating CD71 as an Anti-Cancer Target and Supporting Phase 2 Development Strategy of Potential First-in-Class Drug Candidate

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported strong financial results for the third quarter ended September 30, 2020, as well as the following operational and performance highlights.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced it will provide its proprietary investigational GPR119 agonist, MBX-2982, and will assist in regulatory filings for a clinical study to be conducted by the TRI